fluoroethylnormemantine

Fluoroethylnormemantine (FENM) is a small molecule derivative of memantine, structurally characterized as 3-(2-fluoroethyl)adamantan-1-amine. It acts as a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, similar to memantine but with distinct pharmacological properties. FENM exhibits neuroprotective, anti-amnesic, antidepressant-like, and fear-reducing effects in preclinical models. In mouse models of Alzheimer’s disease (AD), FENM has demonstrated efficacy in preventing cognitive deficits and reducing neuroinflammation and amyloid pathology when administered chronically before symptom onset. Unlike memantine, FENM does not produce amnesic effects at higher doses and shows superior neuroprotective activity against amyloid-beta-induced toxicity. Additionally, it has shown potential as an antidepressant by attenuating stress-induced maladaptive behaviors without the side effects associated with ketamine or memantine[1][2][3][4][7].

Other names

3-(2-fluoroethyl)adamantan-1-amine(18F)-fluoroethylnormemantine